Cargando…

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine

BACKGROUND: A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. MATERIALS AND METHODS: This is a cost-effectiveness analysis performed as a cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Javan-Noughabi, Javad, Rezapour, Aziz, Kassani, Aziz, Hatam, Nahid, Ahmadloo, Niloofar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040151/
https://www.ncbi.nlm.nih.gov/pubmed/30057641
http://dx.doi.org/10.4103/jrms.JRMS_644_17
_version_ 1783338806096691200
author Javan-Noughabi, Javad
Rezapour, Aziz
Kassani, Aziz
Hatam, Nahid
Ahmadloo, Niloofar
author_facet Javan-Noughabi, Javad
Rezapour, Aziz
Kassani, Aziz
Hatam, Nahid
Ahmadloo, Niloofar
author_sort Javan-Noughabi, Javad
collection PubMed
description BACKGROUND: A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. MATERIALS AND METHODS: This is a cost-effectiveness analysis performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost-effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis. RESULTS: The estimated total cost of AC and PG per patient was 1565.23 ± 765.31 and 2099.08 ± 926.99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost-effectiveness ratio results showed AC is a dominate alternative. CONCLUSION: Overall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG.
format Online
Article
Text
id pubmed-6040151
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-60401512018-07-27 The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine Javan-Noughabi, Javad Rezapour, Aziz Kassani, Aziz Hatam, Nahid Ahmadloo, Niloofar J Res Med Sci Original Article BACKGROUND: A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. MATERIALS AND METHODS: This is a cost-effectiveness analysis performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost-effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis. RESULTS: The estimated total cost of AC and PG per patient was 1565.23 ± 765.31 and 2099.08 ± 926.99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost-effectiveness ratio results showed AC is a dominate alternative. CONCLUSION: Overall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG. Medknow Publications & Media Pvt Ltd 2018-06-06 /pmc/articles/PMC6040151/ /pubmed/30057641 http://dx.doi.org/10.4103/jrms.JRMS_644_17 Text en Copyright: © 2018 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Javan-Noughabi, Javad
Rezapour, Aziz
Kassani, Aziz
Hatam, Nahid
Ahmadloo, Niloofar
The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
title The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
title_full The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
title_fullStr The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
title_full_unstemmed The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
title_short The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
title_sort cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040151/
https://www.ncbi.nlm.nih.gov/pubmed/30057641
http://dx.doi.org/10.4103/jrms.JRMS_644_17
work_keys_str_mv AT javannoughabijavad thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT rezapouraziz thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT kassaniaziz thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT hatamnahid thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT ahmadlooniloofar thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT javannoughabijavad costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT rezapouraziz costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT kassaniaziz costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT hatamnahid costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine
AT ahmadlooniloofar costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine